6 / 12
Neurosurg, an open access journal
ISSN: 2471-9633
Page 30
Notes:
August 14-16, 2017 | Toronto, Canada
BRAIN DISORDERS AND DEMENTIA CARE
4
th
International Conference on
allied
academies
Babak Kateb
Neuroscientist, Canada
Traumatic Brain Injury
T
raumatic brain injury (TBI) is an enormous public health
problem, with 1.7 million new cases of TBI recorded
annually by the Centers for Disease Control. However, TBI
has proven to be an extremely challenging condition to treat.
Here, we apply a nanoprodrug strategy in a mouse model
of TBI. The novel nanoprodrug contains a derivative of the
nonsteroidal anti-inflammatory drug (NSAID) ibuprofen
in an emulsion with the antioxidant a-tocopherol. The
ibuprofen derivative, Ibu2TEG, contains a tetra ethylene
glycol (TEG) spacer consisting of biodegradable ester bonds.
The biodegradable ester bonds ensure that the prodrug
molecules break down hydrolytically or enzymatically. The
drug is labeled with the fluorescent reporter Cy5.5 using
nonbiodegradable bonds to 1-octadecanethiol, allowing
us to reliably track its accumulation in the brain after TBI.
We delivered a moderate injury using a highly reproducible
mouse model of closed-skull controlled cortical impact to the
parietal region of the cortex, followed by an injection of the
nano prodrug at a dose of 0.2 mg per mouse. The blood brain
barrier is known to exhibit increased permeability at the site
of injury. We tested for accumulation of the fluorescent
drug particles at the site of injury using confocal and
bioluminescence imaging of whole brains and brain slices
36 hours after administration. We demonstrated that the
drug does accumulate preferentially in the region of injured
tissue, likely due to an enhanced permeability and retention
(EPR) phenomenon. The use of a nanoprodrug approach to
deliver therapeutics in TBI represents a promising potential
therapeutic modality.
Speaker Biography
Babak Kateb, MD is a neuroscientist with more than 20 years of research experience.
His research has been focused on introduction of advance diagnostics and therapeu-
tics into clinical neuroscience in order to rapidly identify and introduce game changing
technologies to treat neurological disorders such as brain cancer, Alzheimer’s disease,
Parkinson’s disease, and other brain and spinal disorders. He did his educational train-
ing at TUSOM, USC, did his research fellowship at USC-keck School of Medicine, De-
partment of Neurosurgery and also studied VLSI system design at USC Department of
Electrical Engineering at the Ming Hsieh Institute.
e:
Babak.Kateb@WorldBrainMapping.orgBabak Kateb, Neurosurg 2017, 2:2
DOI: 10.21767/2471-9633-C1-004